Beckman Coulter Completes Olympus Dx Buy | GenomeWeb

NEW YORK (GenomeWeb News) – Beckman Coulter has completed its $780 million acquisition of Olympus' lab-based diagnostics business, the firm announced over the weekend.

Beckman funded the acquisition with $495 million that was raised through the issuance of two, $250 million senior note offerings, and around $240 million from a common stock offering of approximately 4.7 million shares issued to the public at a price of $53 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.